Venetoclax plus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) improves outcomes in BCL2-positive first-line diffuse large B-cell lymphoma (DLBCL): First safety, efficacy and biomarker analyses from the phase II CAVALLI study Meeting Abstract
| Authors: | Morschhauser, F.; Feugier, P.; Flinn, I. W.; Gasiorowski, R. E.; Greil, R.; Illes, A.; Johnson, N. A.; Larouche, J. F.; Lugtenburg, P. J.; Patti, C.; Salles, G.; Trneny, M.; de Vos, S.; Mir, F.; Kornacker, M.; Punnoose, E. A.; Samineni, D.; Szafer-Glusman, E.; Petrich, A.; Sinha, A.; Mobasher, M.; Zelenetz, A. D. |
| Abstract Title: | Venetoclax plus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) improves outcomes in BCL2-positive first-line diffuse large B-cell lymphoma (DLBCL): First safety, efficacy and biomarker analyses from the phase II CAVALLI study |
| Meeting Title: | 60th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 132 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2018 Dec 1-4 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2018-11-29 |
| Language: | English |
| ACCESSION: | WOS:000454837602160 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood-2018-99-118519 |
| Notes: | Meeting Abstract: 782 -- Source: Wos |
